Literature DB >> 18440264

Effects of lubiprostone on human uterine smooth muscle cells.

John Cuppoletti1, Danuta H Malinowska, Jayati Chakrabarti, Ryuji Ueno.   

Abstract

Lubiprostone, a bicyclic fatty acid derivative and member of a new class of compounds called prostones, locally activates ClC-2 Cl(-) channels without activation of prostaglandin receptors. The present study was specifically designed to test and compare lubiprostone and prostaglandin effects at the cellular level using human uterine smooth muscle cells. Effects on [Ca(2+)](i), membrane potential and [cAMP](i) in human uterine smooth muscle cells were measured. 10 nM lubiprostone significantly decreased [Ca(2+)](i) from 188 to 27 nM, which was unaffected by 100 nM SC-51322, a prostaglandin EP receptor antagonist. In contrast 10nM PGE(2) and PGE(1) both increased [Ca(2+)](i) 3-5-fold which was blocked by SC-51322. Similarly, lubiprostone and prostaglandins had opposite/different effects on membrane potential and [cAMP](i). Lubiprostone caused SC-51322-insensitive membrane hyperpolarization and no effect on [cAMP](i). PGE(2) and PGE(1) both caused SC-51322-sensitive membrane depolarization and increased [cAMP](i). Lubiprostone has fundamentally different cellular effects from prostaglandins that are not mediated by EP receptors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18440264     DOI: 10.1016/j.prostaglandins.2008.03.001

Source DB:  PubMed          Journal:  Prostaglandins Other Lipid Mediat        ISSN: 1098-8823            Impact factor:   3.072


  14 in total

Review 1.  New treatment options for chronic constipation: mechanisms, efficacy and safety.

Authors:  Michael Camilleri
Journal:  Can J Gastroenterol       Date:  2011-10       Impact factor: 3.522

2.  Prokinetic effects of large-dose lubiprostone on gastrointestinal transit in dogs and its mechanisms.

Authors:  Jun Song; Jieyun Yin; Xiaohong Xu; Jiande Chen
Journal:  Am J Transl Res       Date:  2015-03-15       Impact factor: 4.060

Review 3.  ClC-2 regulation of intestinal barrier function: Translation of basic science to therapeutic target.

Authors:  Younggeon Jin; Anthony T Blikslager
Journal:  Tissue Barriers       Date:  2015-11-13

4.  Lubiprostone activates Cl- secretion via cAMP signaling and increases membrane CFTR in the human colon carcinoma cell line, T84.

Authors:  Mei Ao; Jayashree Venkatasubramanian; Chaiwat Boonkaewwan; Nivetha Ganesan; Asma Syed; Richard V Benya; Mrinalini C Rao
Journal:  Dig Dis Sci       Date:  2010-12-08       Impact factor: 3.199

5.  Lubiprostone stimulates secretion from tracheal submucosal glands of sheep, pigs, and humans.

Authors:  N S Joo; J J Wine; A W Cuthbert
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-02-20       Impact factor: 5.464

6.  Lubiprostone: evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndrome.

Authors:  Tisha N Lunsford; Lucinda A Harris
Journal:  Int J Womens Health       Date:  2010-10-27

7.  Lubiprostone ameliorates the cystic fibrosis mouse intestinal phenotype.

Authors:  Robert C De Lisle; Racquel Mueller; Eileen Roach
Journal:  BMC Gastroenterol       Date:  2010-09-15       Impact factor: 3.067

Review 8.  Review article: new receptor targets for medical therapy in irritable bowel syndrome.

Authors:  M Camilleri
Journal:  Aliment Pharmacol Ther       Date:  2010-01       Impact factor: 8.171

9.  Lubiprostone: clinical applications beyond constipation.

Authors:  Shailendra Kapoor
Journal:  World J Gastroenterol       Date:  2009-03-07       Impact factor: 5.742

10.  Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects.

Authors:  Seth Sweetser; Irene A Busciglio; Michael Camilleri; Adil E Bharucha; Lawrence A Szarka; Athanasios Papathanasopoulos; Duane D Burton; Deborah J Eckert; Alan R Zinsmeister
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-11-25       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.